Prot #PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Project: Research project

Project Details

StatusActive
Effective start/end date5/27/155/20/23

Funding

  • Janssen Research & Development, LLC (Prot #PCI-32765CAN3001)